Please assess the completion status of the following clinical trial:

Trial Title: Granulocytapheresis in Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Moderate to severe plaque psoriasis with a PASI \>/=10~* Age \>/= 18 years~* Negative pregnancy test in woman of childbearing age acceptable method of contraception for both men and women~* Written informed consent that can be withdrawn at any time or for any reason~* Discontinuation of any systemic psoriasis treatment. Washout period of at least two weeks for prior systemic medications~* Only emollients for topical treatment~* No vaccinations for at least 14 days prior to first treatment~Exclusion Criteria:~* Other forms of psoriasis (e.g., guttate, pustular, erythrodermic, palmoplantar etc.)~* History of ongoing uncontrolled bacterial, fungal or viral infection (including opportunistic infections); HIV positivity~* Pregnancy~* Clinically relevant thrombocytopenia or bleeding disorders~* WBC \<4.000 or \>12.000/µl~* Malignancy within the last five years (exception: successfully treated basal cell carcinoma or squamous cell carcinoma of the skin)~* Severe cardiac disorders, stroke, pulmonary disease within the last year~* Any medical condition that, in the judgment of the investigators, would jeopardize the patient's safety during the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): Granulocytapheresis treatment
- B (Type: PLACEBO_COMPARATOR): Sham device treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).